Cargando…
Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy
We retrospectively analyzed the clinical and laboratory data of patients diagnosed with anti-transcriptional intermediary factor 1 (TIF-1γ) antibody-positive polymyositis (PM)/dermatomyositis (DM) to clarify the characteristics of this disease. We identified 14 patients with TIF-1γ antibody-positive...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999723/ https://www.ncbi.nlm.nih.gov/pubmed/35407533 http://dx.doi.org/10.3390/jcm11071925 |
_version_ | 1784685257775120384 |
---|---|
author | Harada, Yumi Tominaga, Masaki Iitoh, Eriko Kaieda, Shinjiro Koga, Takuma Fujimoto, Kiminori Chikasue, Tomonori Obara, Hitoshi Kakuma, Tatsuyuki Ida, Hiroaki Kawayama, Tomotaka Hoshino, Tomoaki |
author_facet | Harada, Yumi Tominaga, Masaki Iitoh, Eriko Kaieda, Shinjiro Koga, Takuma Fujimoto, Kiminori Chikasue, Tomonori Obara, Hitoshi Kakuma, Tatsuyuki Ida, Hiroaki Kawayama, Tomotaka Hoshino, Tomoaki |
author_sort | Harada, Yumi |
collection | PubMed |
description | We retrospectively analyzed the clinical and laboratory data of patients diagnosed with anti-transcriptional intermediary factor 1 (TIF-1γ) antibody-positive polymyositis (PM)/dermatomyositis (DM) to clarify the characteristics of this disease. We identified 14 patients with TIF-1γ antibody-positive DM (TIF-1γ DM), 47 with anti-aminoacyl-tRNA synthetase antibody (ARS)-positive PM/DM, and 24 with anti-melanoma differentiation-associated gene 5 antibody (MDA-5)-positive PM/DM treated at the Kurume University Hospital between 2002 and 2020. Patients with TIF-1γ DM were significantly older than the other two groups. Nine patients with TIF-1γ DM were female, thirteen patients had DM, and one had clinically amyopathic DM. Primary malignant lesions were lung (3), uterus (2), colon (2), breast (2), ovary (1), lymphoma (1), and unknown (2). Cutaneous manifestation and dysphagia were the most common symptoms in TIF-1γ DM. Erythema (9/14), the V-neck sign (8/14), heliotrope (9/14), and nailfold telangiectasia (14/14) were significantly more common in TIF-1γ DM. Furthermore, no patients with TIF-1γ DM had interstitial lung abnormality on high-resolution CT. In patients with TIF-1γ DM, the frequency of dysphagia and unusual erythema, particularly that which spreads from the trunk, and nailfold telangiectasia, were characteristic findings. In most patients with TIF-1γ DM, it is necessary to administer other immunosuppressive drugs along with glucocorticoids. |
format | Online Article Text |
id | pubmed-8999723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89997232022-04-12 Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy Harada, Yumi Tominaga, Masaki Iitoh, Eriko Kaieda, Shinjiro Koga, Takuma Fujimoto, Kiminori Chikasue, Tomonori Obara, Hitoshi Kakuma, Tatsuyuki Ida, Hiroaki Kawayama, Tomotaka Hoshino, Tomoaki J Clin Med Article We retrospectively analyzed the clinical and laboratory data of patients diagnosed with anti-transcriptional intermediary factor 1 (TIF-1γ) antibody-positive polymyositis (PM)/dermatomyositis (DM) to clarify the characteristics of this disease. We identified 14 patients with TIF-1γ antibody-positive DM (TIF-1γ DM), 47 with anti-aminoacyl-tRNA synthetase antibody (ARS)-positive PM/DM, and 24 with anti-melanoma differentiation-associated gene 5 antibody (MDA-5)-positive PM/DM treated at the Kurume University Hospital between 2002 and 2020. Patients with TIF-1γ DM were significantly older than the other two groups. Nine patients with TIF-1γ DM were female, thirteen patients had DM, and one had clinically amyopathic DM. Primary malignant lesions were lung (3), uterus (2), colon (2), breast (2), ovary (1), lymphoma (1), and unknown (2). Cutaneous manifestation and dysphagia were the most common symptoms in TIF-1γ DM. Erythema (9/14), the V-neck sign (8/14), heliotrope (9/14), and nailfold telangiectasia (14/14) were significantly more common in TIF-1γ DM. Furthermore, no patients with TIF-1γ DM had interstitial lung abnormality on high-resolution CT. In patients with TIF-1γ DM, the frequency of dysphagia and unusual erythema, particularly that which spreads from the trunk, and nailfold telangiectasia, were characteristic findings. In most patients with TIF-1γ DM, it is necessary to administer other immunosuppressive drugs along with glucocorticoids. MDPI 2022-03-30 /pmc/articles/PMC8999723/ /pubmed/35407533 http://dx.doi.org/10.3390/jcm11071925 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Harada, Yumi Tominaga, Masaki Iitoh, Eriko Kaieda, Shinjiro Koga, Takuma Fujimoto, Kiminori Chikasue, Tomonori Obara, Hitoshi Kakuma, Tatsuyuki Ida, Hiroaki Kawayama, Tomotaka Hoshino, Tomoaki Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy |
title | Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy |
title_full | Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy |
title_fullStr | Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy |
title_full_unstemmed | Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy |
title_short | Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy |
title_sort | clinical characteristics of anti-tif-1γ antibody-positive dermatomyositis associated with malignancy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999723/ https://www.ncbi.nlm.nih.gov/pubmed/35407533 http://dx.doi.org/10.3390/jcm11071925 |
work_keys_str_mv | AT haradayumi clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT tominagamasaki clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT iitoheriko clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT kaiedashinjiro clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT kogatakuma clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT fujimotokiminori clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT chikasuetomonori clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT obarahitoshi clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT kakumatatsuyuki clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT idahiroaki clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT kawayamatomotaka clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy AT hoshinotomoaki clinicalcharacteristicsofantitif1gantibodypositivedermatomyositisassociatedwithmalignancy |